Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

Vaccine

Volumn 32, Issue 6, 2014, Pages 733-739

  Van Kriekinge, Georges ^a   Castellsagué, Xavier ^b   Cibula, David ^c   Demarteau, Nadia ^a  

^a GSK   (Belgium)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cervical cancer; Human papillomavirus; Vaccination

Indexed keywords

ADJUVANT; WART VIRUS VACCINE;

ARTICLE; BRAZIL; CANADA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CROSS PROTECTION; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ITALY; MAJOR CLINICAL STUDY; MALAYSIA; PAPILLOMAVIRUS INFECTION; PRECANCER; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CC; CERVICAL CANCER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CIN; HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION; HPV; HSIL; HUMAN PAPILLOMAVIRUS; ICO; INSTITUT CATALÀ D'ONCOLOGIA; LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE.; LEEP; LLETZ; LOOP ELECTROSURGICAL EXCISION PROCEDURE; TOTAL VACCINATED COHORT; TVC; VACCINATION; VACCINE EFFICACY; VE; WHO; WORLD HEALTH ORGANIZATION;

CANADA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HUMANS; MASS VACCINATION; MEXICO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOUTH AFRICA; THAILAND; UTERINE CERVICAL NEOPLASMS;

EID: 84892988680     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.049     Document Type: Article

References (29)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide in 2008 2010, IARC CancerBase No. 10, http://globocan.iarc.fr/ cited 2012 Mar 19.
2. ICO.ICO (Institut Català d'Oncologia) Information Centre on HPV and Cancer (HPV Information Centre) Data Query tool 2013, http://www.hpvcentre.net/dataquery.php/ cited 2013 Jul 1.
3. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 Sep, 189(1):12-19.
4. Clifford G.M., Smith J.S., Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003 Jan 13, 88(1):63-73.
5. Aljunid S., Zafar A., Saperi S., Amrizal M. Burden of disease associated with cervical cancer in Malaysia and potential costs and consequences of HPV vaccination. Asian Pac J Cancer Prev 2010, 11(6):1551-1559.
6. Updated consensus guidelines for managing abnormal cervical cancer screening tests and cancer precursors 2012, American Society for Colposcopy and Cervical Pathology (ASCCP), Frederick, MD, USA.
7. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 30 June, 369(9580):70-2161.
8. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 6 July, 374(9686):301-314.
9. Lehtinen M., Paavonen J., Wheeler C.M., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 Jan 2012, 1:89-99.
10. Wheeler C.M., Castellsague X., Garland S.M., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 Jan 13, 1:100-110.
11. Introduction of HPV vaccines in European Union countries-an update 2012, European Centre for Disease Prevention and Control, Stockholm, in press.
12. FDA licensure of bivalent human papillomavirus vaccine (HPV2 Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee of Immunization Practices (ACIP). MMWR 2010 May 28, 59(20):626-629.
13. World Bank PPP conversion factor, GDP (LCU per international $) 2012, http://data.worldbank.org/indicator/PA.NUS.PPP?display=default/ cited 2012 Dec 4.
14. Colantonio L., Gomez J.A., Demarteau N., Standaert B., Pichon-Riviere A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009 Sep 4, 27(40):29-5519.
15. Anonychuk A.M., Bauch C.T., Merid M.F., Van Kriekinge G., Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401.
16. Hillemanns P., Petry K., Largeron N., McAllister R., Tolley K., Büsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J of Public Health 2009 1 April, 17(2):77-86.
17. Siebert U., Sroczynski G., Hillemanns P., et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006 April, (2):185-192.
18. Van Enckevort P.J., Kongngamkam K., Van Kriekinge G. Costs and consequences of HPV vaccination in Thailand: results of a prevalence based model. (Abstract PCN62 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress, 5-8 Nov, Madrid, Spain). Value Health 2011, 14(7):A445.
19. Sinanovic E., Moodley J., Barone M.A., Mall S., Cleary S., Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27(44):202-6196.
20. World Bank Consumer price index (2005=100) 2012, http://data.worldbank.org/indicator/FP.CPI.TOTL/countries/1W?display=default [cited 2012 Sep 11].
21. Capri S., Gasparini R., Panatto D., Demarteau N. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. Gynecol Oncol 2011 June 1, 121(3):514-521.
22. Insinga R.P., Glass A.G., Rush B.B. The health care costs of cervical human papillomavirus - related disease. Am J Obstet Gynecol 2004 July, 191(1):114-120.
23. Annemans L., Remy V., Lamure E., et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008, 11(1):135-150.
24. Arbyn M., Kyrgiou M., Simoens C., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008, 337:a1284.
25. Bruinsma F.J., Quinn M.A. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 2011 Aug, 118(9):41-1031.
26. Sow P.S., Watson-Jones D., Kiviat N., et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J Infect Dis 2012 Dec 13.
27. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011 June 18, 377(9783):92-2085.
28. Moscicki A.B., Wheeler C.M., Romanowski B., et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012 Dec 17, 31(1):234-241.
29. Kemp T.J., Safaeian M., Hildesheim A., et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R)). Vaccine 2012, 31(1):165-170.